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Background
The existence of multiple subsets of chronic lymphocytic leukemia expressing ‘stereotyped’ B-
cell receptors implies the involvement of antigen(s) in leukemogenesis. Studies also indicate
that ‘stereotypy’ may influence the clinical course of patients with chronic lymphocytic
leukemia, for example, in subsets with stereotyped IGHV3-21 and IGHV4-34 B-cell receptors;
however, little is known regarding the genomic profile of patients in these subsets.
Design and Methods
We applied 250K single nucleotide polymorphism-arrays to study copy-number aberrations
and copy-number neutral loss-of-heterozygosity in patients with stereotyped IGHV3-21 (sub-
set #2, n=29), stereotyped IGHV4-34 (subset #4, n=17; subset #16, n=8) and non-subset #2
IGHV3-21 (n=13) and non-subset #4/16 IGHV4-34 (n=34) patients.
Results
Over 90% of patients in subset #2 and non-subset #2 carried copy-number aberrations, where-
as 75-76% of patients in subset #4 and subset #16 showed copy-number aberrations. Subset #2
and non-subset #2 patients also displayed a higher average number of aberrations compared to
patients in subset #4. Deletion of 13q was the only known recurrent aberration detected in sub-
set #4 (35%); this aberration was even more frequent in subset #2 (79%). del(11q) was more
frequent in subset #2 and non-subset #2 (31% and 23%) patients than in subset #4 and non-
subset #4/16 patients. Recurrent copy-number neutral loss-of-heterozygosity was mainly
detected on chromosome 13q, independently of B-cell receptor stereotypy. 
Conclusions
Genomic aberrations were more common in subset #2 and non-subset #2 than in subset #4.
The particularly high frequency of del(11q) in subset #2 may be linked to the adverse outcome
reported for patients in this subset. Conversely, the lower prevalence of copy-number aberra-
tions and the absence of poor-prognostic aberrations in subset #4 may reflect an inherently
low-proliferative disease, which would prevent accumulation of genomic alterations. 
Key words: chronic lymphocytic leukemia, stereotyped B-cell receptors, antigens, leukemoge-
nesis.
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Introduction
In chronic lymphocytic leukemia (CLL), the mutation
status of the immunoglobulin heavy chain variable (IGHV)
genes has emerged as one of the strongest prognostic
markers, since it divides patients into two clinical sub-
groups, those with IGHV-mutated and those with IGHV-
unmutated CLL, with different prognoses.1,2 Furthermore,
CLL displays a remarkably biased IGHV repertoire with
over-representation of a limited number of genes, such as
IGHV1-69, IGHV4-34, IGHV3-23 and IGHV3-21.2-4
Several groups have reported multiple CLL subsets with
almost identical, ‘stereotyped’ B-cell receptors (BCR) in up
to about 30% of patients.3,5-11 These subsets are defined by
certain criteria such as usage of similar IGHV-D-J genes
and light-chain genes and an amino acid identity of 60% or
more in the heavy-chain complementarity determining
region 3 (CDR3), which is the main determinant of antigen
specificity.6,8-10 Considering the very low probability of
finding two B-cell clones with almost identical BCR by
chance alone, these findings have supported the notion
that the development of CLL is not stochastic and suggests
a potential role for antigens in leukemogenesis through the
recognition of similar epitopes within each subset. 
So far, more than 100 different subsets have been
defined with stereotyped BCR, with some of the subsets
being more frequent than others.9,10 Interestingly, CLL sub-
sets expressing a certain stereotyped BCR have also been
indicated to share biological and clinical features.9,12 For
instance, IGHV4-34/IGKV2-30 patients with stereotyped
BCR (20 amino acids long, known as subset #4) have an
indolent disease course compared to those with non-
stereotyped IGHV4-34.9 Furthermore, subset #4 patients
have a low median age at diagnosis, IgG-switched BCR6,9,13
and a potential association with persistent infection by
common herpesviruses.14 Another IGHV4-34 subset, sub-
set #16 (IGHV4-34/IGKV3-20, with a CDR3 that is 24
amino acids long), has been identified, although less is
known about the clinical outcome for these patients.
Approximately half of the patients with IGHV3-21 CLL
display a stereotyped BCR (known as subset #2) with a
short and highly similar CDR3 (9 amino acids long) and
usage of one particular IG lambda gene, IGLV3-21.5,12,15
However, it appears that IGHV3-21 patients with stereo-
typed and non-stereotyped BCR share an equally poor
overall survival, independently of IGHV mutational sta-
tus5,15,16 although stereotypy has been associated with a
shorter time to progression and the presence of other
markers of a poor prognosis.9,17
No single genetic event has been found in all cases of
CLL, although certain recurrent aberrations (e.g. deletions
of 13q, 11q, 17p and trisomy 12) are frequently detected
and can assist outcome prediction.18 Patients carrying
del(13q) as the sole abnormality have a favorable progno-
sis,19 whereas patients with del(11q) (ATM) and del(17p)
(TP53) have an inferior outcome.18 Until now, few studies
have investigated genomic aberrations specifically in rela-
tion to CLL subsets with stereotyped BCR. In one study,
fluorescence in situ hybridization (FISH) analysis indicated
a higher frequency of del(11q) in IGHV3-21 CLL15 and, in
another study, del(13q) was detected more frequently in
IGHV4-34 subset #4 patients than in non-subset patients,
who carried more heterogeneous aberrations.20
Since genomic profiling of stereotyped subsets might
offer clues about the underlying leukemic processes, we
here applied 250K single nucleotide polymorphism (SNP)-
arrays to investigate the presence of whole-genome copy-
number aberrations and copy-number neutral loss of het-
erozygosity (CNN-LOH) in CLL patients with stereotyped
and non-stereotyped IGHV3-21 and IGHV4-34 BCR.
These relatively common subsets were chosen for analy-
sis as they display distinctive as well as divergent clinical
and biological features. 
Design and Methods
Groups of patients 
In total, 101 CLL patients from collaborating institutes in France
(n=15), Greece (n=25), Denmark (n=4) and Sweden (n=57) were
studied. Most samples were derived from peripheral blood (n=88),
but samples from bone marrow (n=8) and spleen (n=5) were also
included. All samples were diagnosed according to recently
revised criteria for CLL,21 and showed a typical immunopheno-
type and 70% or more tumor cells. Clinical data for all patients are
summarized in Table 1. Subsets were defined according to
Stamatopoulos et al. and Murray et al.9,10 Twenty-nine samples
were classified as subset #2 (IGHV3-21/IGLV3-21 usage, CDR3 of
9 amino acids long) and 13 samples as non-subset #2 (IGHV3-21
usage, heterogeneous CDR3 lengths). Seventeen samples were
defined as subset #4 (IGHV4-34/IGKV2-30 usage, CDR3 of 20
amino acids long, IgG-switched), 8 samples as subset #16 (IGHV4-
34/IGKV3-20 usage, CDR3 of 24 amino acids long) and 34 as non-
subset #4/16 (IGHV4-34 usage, heterogeneous CDR3 lengths).
Single nucleotide polymorphism-array analysis
SNP-array experiments were performed according to the stan-
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Table 1. Clinical data for IGHV3-21 and IGHV4-34 chronic lymphocytic
leukemia subgroups included in this study.
Samples Subset Non-subset Subset Subset Non-subset
(n=101) #2 #2 #4 #16 #4/16
(n= 29) (n=13) (n=17) (n=8) (n=34)
Sex 
Male 19 6 8 3 23
Female 10 7 9 5 1
Median age 62 63 57 68 60
at diagnosis (50-86) (45-82) (37-72) (52-78) (42-72)
years (range)
Binet stage 
A 12 4 14 6 27
B 8 4 2 1 1
C 2 2 0 0 1 
Not defined 7 3 1 1 5
IGHVmutation 
statusa
Mutated 20 5 17 8 27 
Unmutated 9 8 0 0 7
Treatedb
Yes 7 2 2 1 14 
No 13 8 14 7 15
Not defined 9 3 1 0 5
Alive
Yes 13 3 15 6 28 
No 14 9 2 1 5 
Not defined 2 1 0 1 1
aCases with ≥98% identity to germline were classified as unmutated, whereas cases with <98%
identity were considered mutated. bDenotes treatment status of patient at sampling.  Classified as
stereotyped (subset) or non-stereotyped (non-subset) according to previously defined criteria.9,10
dard protocols for Affymetrix GeneChip® Mapping NspI-250K
arrays (Gene Chip Mapping 500K Assay Manual (P/N 701930
Rev2.), Affymetrix Inc., Santa Clara, CA, USA) and the arrays were
scanned using the GeneChip® Scanner 3000 7G. Genotype calling
and probe level normalization were performed in the Affymetrix
GeneChip® Genotyping Analysis Software (GTYPE) 4.1 using the
Dynamic Model (DM) algorithm and BRLMM.22 The quality con-
trol specifies a neighbor score that represents the average of the
Euclidean distances between the log2ratio of flanking SNP along
the chromosomes. Low neighbor scores indicate a low noise level:
a neighbor score of 0.4 or less was, therefore, applied as the cut-off
for inclusion of samples. In order to produce log2ratios, copy-num-
ber normalization was performed using the Copy Number
Analysis Tool (CNAT) 4.0.1. Normal samples (n=82) analyzed at
the Uppsala Array Platform were used as a reference set.
Analysis of Affymetrix data for copy-number alterations
Copy-number analysis using the rank segmentation algorithm
and group comparisons were performed employing BioDiscovery
Nexus Copy Number 3.0 software (BioDiscovery, El Segundo CA,
USA). Copy-number analysis was performed using a significance
threshold (P value) of 1x10-6 and a log2ratio cut-off at ±0.2 for
regions sized 200-500 kbp and ±0.15 for regions longer than 500
kbp. These settings were defined through validation experiments
in a previously described sample-set including 203 CLL samples.23
Copy-number variations are genomic variants that exist in the
human population and these polymorphic regions can be detected
as gains and losses.24 To exclude such polymorphic regions, we
compared the regions detected in the copy-number analysis to fre-
quent regions of copy-number variations reported by Redon et al.25
and MacCarroll et al.26 Regions that overlapped by less than 50%
with copy-number variations were considered as true copy-num-
ber aberrations and included in the final analysis, as previously
described.23
Copy-number neutral loss-of-heterozygosity analysis
Analysis of CNN-LOH in CLL cells was performed using SNP
array-data, taking into account the fraction of normal cells
obtained from the flow-cytometry data, as previously described.27
CNN-LOH regions were visualized by mapping them to 200 kb
segments beginning at the chromosome start site. Regions con-
taining CNN-LOH larger than 3 Mbp with less than 50% overlap
with copy-number variations were considered for further analysis.
Statistical analysis
Statistical analysis was performed using the Statistica Software
8.0 (Stat Soft Inc., Tulsa, OK, USA). A χ2 test was applied to deter-
mine any statistically significant differences in the frequency of
the known recurrent aberrations between the studied groups (sub-
sets/non-subsets and our general Swedish CLL cohort). Similarly,
the one-way ANOVA test and t-test were applied to determine
any statistically significant differences in the number and size of
copy-number aberrations between groups of patients. 
Results
We investigated stereotyped and non-stereotyped
IGHV3-21 and IGHV4-34 CLL samples using high-densi-
ty 250K SNP arrays, with particular interest in detecting
genomic alterations in these specific subsets. Figure 1
shows the distributions of the number and size of copy-
number aberrations in the various subsets, while details
concerning the known recurrent aberrations found in
these subgroups are provided in Figure 2 and Table 2.
IGHV3-21 chronic lymphocytic leukemia - subset #2
versus non-subset #2
Our copy-number analysis showed that 97% (28/29) of
subset #2 and 92% (12/13) of non-subset #2 IGHV3-21
samples carried copy-number aberrations (Figure 1A). Both
subgroups displayed a similar average of copy-number
aberrations/sample (2.6 vs. 2.3 copy-number aberrations/
sample), although non-subset #2 patients carried larger
copy-number aberrations compared to subset #2 (median
size, 1.8 Mbp versus 1.39 Mbp, P=0.001) (Figure 1B, Online
Supplementary Table S1). The known recurrent aberrations
were detected in 90% of subset #2 and 54% of non-subset
#2 patients (Table 2). The majority of subset #2 samples
carried del(13q) (79%), while a smaller proportion of the
non-subset #2 samples (31%) displayed this aberration
(P=0.0024). A particularly high frequency of del(11q) was
detected in subset #2 patients (9/29 samples, 31%) com-
pared with our previous Swedish CLL array-based report
(13%) (P=0.013) (Figure 2).23 Also, a relatively high frequen-
cy of del(11q) was found in non-subset #2 cases (23%).
Furthermore, of the samples with del(11q), 75% (9/12) also
carried del(13q) (Figure 2-3). All 11q deletions were shown
to cover the ATM gene. del(17p), covering the TP53 gene,
and trisomy 12 were only detected in non-subset #2
patients. 
When excluding the known recurrent aberrations, loss-
es were shown to be more common than gains in both
subset #2 and non-subset #2 (Online Supplementary Table
S2). When considering alterations less than or greater than
1 Mbp in size, a similar average of copy-number aberra-
tions/sample was observed within subset #2 and non-sub-
set #2 cases (Online Supplementary Table S1). Only two
other recurrent alterations were identified on chromo-
somes 2q and 3p. Specifically, two subset #2 samples
(6.9%) displayed a gain at 2q32.1 with an average size of
0.21 Mbp. These samples also demonstrated concurrent
deletions of 11q and 13q. Furthermore, two subset #2
samples with 13q deletion demonstrated a loss at 3p21.31-
3p21.1 with an average size of 2.3 Mbp. Here, one non-
subset #2 patient carried del(17p), trisomy 12, a loss at
7q11.21 (0.7 Mbp) and a large novel loss at 16q11.2-16q21
(13.4 Mbp). In addition, large (>20 Mbp) non-recurring
aberrations were identified at 4q, 4p, 5q, 14q and 21q, pre-
dominantly within non-subset #2 cases (Online
Supplementary Table S3). 
IGHV4-34 chronic lymphocytic leukemia - subset #4
versus subset 16 versus non-subset #4/16
Assessment of copy-number aberrations showed that
76% of subset #4 (13/17), 75% of subset #16 (6/8) and
88% of non-subset #4/16 (30/34) IGHV4-34 patients car-
ried such aberrations. The average number of copy-num-
ber aberrations/sample for non-subset #4/16, subset #16
and subset #4 cases were 2.1, 1.5 and 1.3, respectively
(Online Supplementary Table S1). Subset #16 and non-sub-
set #4/16 carried larger aberrations than subset #4 sam-
ples (Figure 1B), although the median size was not statis-
tically different (0.64 Mbp, 0.95 Mbp, 0.74 Mbp, respec-
tively, P=0.24). The known recurrent aberrations were
identified in 35% of subset #4, 25% of subset #16 and
59% of non-subset #4/16 cases (Figure 2 and Table 2).
The exclusive recurrent aberration in subset #4 cases was
deletion of 13q (6/6 cases with known recurrent aberra-
tions). Deletion of 13q was also detected in 44% (15/34)
of non-subset #4/16 cases, while this aberration was
High-density genomic arrays in CLL subsets
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absent in subset #16 cases. Deletion of 11q and trisomy
12 were only detected in subset #16 and non-subset #4/16
samples, whereas del(17p) was only observed in non-sub-
set #4/16 samples (Table 2). 
Upon removal of known recurrent aberrations from the
analysis, losses were more frequent than gains in subset
#4, and non-subset #4/16, but not in subset #16 (Online
Supplementary Table S2). Furthermore, on examination of
alterations greater or less than 1 Mbp, subset #4, subset
#16 and non-subset #4/16 patients showed a similar aver-
age number of copy-number aberrations/sample and a
comparable median length of the aberrations (Online
Supplementary Table S1). Among the IGHV4-34 cases three
recurrent aberrations were revealed. A deletion on 2q37.3
(5 Mbp), covering the telomeric region, was detected in
two subset #4 and two non-subset #4/16 samples. Two
samples in the non-subset #4/16 group showed a gain on
7q34 covering 0.3 Mbp, while one subset #4 and one non-
subset #4/16 case carried an overlapping gain of 14q23.3
with an average size of 0.6 Mbp. Finally, non-recurring,
larger aberrations (>20 Mbp) including trisomy 3, losses of
6q, 14q and gains of 8q, 13q, 22q were only detected in
non-subset #4/16 (Online Supplementary Table S3).
Copy-number neutral loss-of-heterozygosity in IGHV3-
21 and IGHV4-34 chronic lymphocytic leukemia
The evaluation of CNN-LOH, i.e. allelic imbalances
without a change in copy-number, revealed that most
regions were non-recurrent between samples. For
instance, when regions greater than 3 Mp were evaluated,
ten non-overlapping regions were shown in subset
#2/non-subset #2 IGHV3-21 samples, whereas 16 individ-
ual CNN-LOH regions were detected in subset #4 and
non-subset #4/16 IGHV4-34 samples. However, a large
recurrent CNN-LOH was detected on chromosome 13q in
two subset #2, one subset #4 and two non-subset #4/16
samples, all of which carried a homozygous loss of 13q.
Moreover, partially overlapping regions were identified on
chromosome 20q11.21-q11.23 (overlapping region: 3.6
M. Marincevic et al.
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Figure 1. Level of genomic complexity and size distribution of copy-
number aberrations. The columns represent IGHV4-34 samples; sub-
set #4 (n=17), subset #16 (n=8) and non-subset #4/16 (n=34);
IGHV3-21 samples; subset #2 (n=29) and non-subset #2 (n=13) and
a ‘general’ CLL cohort (n=203) from the study by Gunnarsson et al.23
Samples from the current study that overlapped with our recent array-
based Swedish CLL cohort study23 were not removed from analysis, as
the overlap between studies was limited. (A) Level of genomic com-
plexity in each group is based on the frequency of samples that carry
a certain number of CNAs (0, 1, 2 or ≥3). (B) The size distribution of
copy-number aberrations (<1 Mbp, 1-5 Mbp or >5 Mbp) is shown as
the frequency of the total number of copy-number aberrations. Note
that subset #4 samples do not carry copy-number aberrations greater
than 5 Mbp, whereas the non-subset #2 samples show the highest fre-
quency of copy-number aberrations greater than 5 Mbp.
Figure 2. Frequency of patients carrying deletions of 11q and 13q
individually or in combination. Each pie represents IGHV3-21 sam-
ples in subset #2 (n=29) and non-subset #2 (n=13), IGHV4-34 sam-
ples in subset #4 (n=17), subset #16 (n=8) and non-subset #4/16
(n=34), and a ‘general’ CLL cohort (n=203) from the study by
Gunnarsson et al.23 Samples that carry ‘Any CNA' also include
del(17p) and trisomy 12, which were infrequently detected in this
study, as indicated in Table 2.
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Mbp) in one subset #2 and one non-subset #2 IGHV3-21
sample. Among the IGHV4-34 patients, two non-subset
#4/16 samples had an overlapping CNN-LOH of 3.2 Mbp
on chromosome 6p22.1. 
Discussion
Recently, several groups have reported multiple CLL
subsets carrying closely homologous BCR with similar
heavy and light-chain CDR3 sequences.6-10 These stereo-
typed BCR suggest a potential role for antigens in leuke-
mogenesis, a hypothesis also supported by recent studies
detailing the BCR specificity in CLL.28-32 Interestingly,
patients in CLL subsets expressing a certain stereotyped
BCR have been indicated to share biological and clinical
features, for instance IGHV3-21 subset #2 patients and
IGHV4-34 subset #4 patients.9,12 Despite this, limited
knowledge exists about the spectrum of genomic aberra-
tions that occur in these different subsets, although such
information might give hints of important genetic events
occurring during disease development and/or evolution.
To gain knowledge on this issue, we used a high-density
SNP array to screen for whole-genome copy-number aber-
rations and CNN-LOH events in stereotyped subset #2
and subset #4/#16 cases and compared them to their non-
stereotyped counterparts. 
Focusing on IGHV3-21 patients, our analysis revealed
that a high frequency of subset #2 and non-subset #2 sam-
ples carried copy-number aberrations. In fact, both subset
#2 and non-subset #2 displayed a similar average number
of copy-number aberrations/sample, which was compara-
ble to the level observed in our recent array-based study
on Swedish CLL.23 Hence, when accounting for all genom-
ic alterations, IGHV3-21 subset #2 and non-subset #2
cases do not appear to be more complex than other cases
of CLL. That notwithstanding, differences were noted in
the frequency of the known recurrent alterations, such as
a high frequency of del(11q) among subset #2 patients
(Figure 2). In fact, the frequency of del(11q) was higher in
subset #2 than in either our Swedish CLL study or other
previously reported FISH studies in CLL,15,18,23 although a
relatively high frequency was also observed in non-subset
#2 patients. 
Both ATM and TP53 are important for maintaining
genomic stability, with the former acting as a positive reg-
ulator of TP53. To assess the possibility that patients car-
rying a deletion of ATM also have TP53 mutations, which
may contribute to an adverse prognosis in CLL, we
sequenced all IGHV3-21 patients with del(11q) in search
of TP53 mutations (exons 4-8). However, none of the
patients displayed any TP53 mutation, which suggests
that the deletion of ATM is sufficient to contribute to the
adverse outcome observed in IGHV3-21-expressing CLL,
particularly in subset #2 patients. Furthermore, the fre-
quency of del(13q) was considerably higher in subset #2
than in non-subset #2 cases or in any other CLL material
reported to date.18,23 These aberrations may represent
important genetic events during the pathogenesis of
IGHV3-21 CLL, particularly when considering the fre-
quent finding of concurrent 11q and 13q deletions, espe-
cially in subset #2 cases (Figures 2 and 3). Hypothetically,
these aberrations may be acquired during the phase of
active stimulation by (unknown) antigens, which trigger
the IGHV3-21 precursor cell to undergo rapid cell division
and hence make it susceptible to clonal alterations.
When investigating subset #4 IGHV4-34 patients, a
group known to have a favorable prognosis with few
patients needing treatment, we observed a significantly
lower average number of aberrations compared to that in
non-subset #4/16, subset #2, non-subset #2 and patients in
our recent array-based study (P=0.0067, Online
Supplementary Table S1).23 This difference was due to the
fact that subset #4 carried a higher number of samples
with no genomic aberrations compared to subset #2 and
non-subset #2 samples (17% versus 5%), and that a larger
proportion of subset#2/non-subset #2 patients displayed a
higher number of copy-number aberrations per sample
(Figure 1). Furthermore, the frequency of samples carrying
the known recurrent alterations was considerably lower in
subset #4 (Table 2). Indeed, the only known recurrent
aberration identified in subset #4 was the favorable prog-
nostic marker del(13q) (Figure 2), albeit detected at a lower
frequency (35%) compared to a recent report, in which
FISH analysis detected del(13q) in 62% of subset #4
cases.20 However, this apparent discrepancy may be attrib-
uted to the fact that many of the subset #4 samples includ-
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Table 2. Known recurrent alterations in IGHV3-21 and IGHV4-34 subsets compared to in a general chronic lymphocytic leukemia cohort.
Subgroup: IGHV3-21 IGHV4-34 General CLL cohort
Subsets: (number) Subset #2 Non-subset #2 Subset #4 Subset #16 Non-subset #4/16 All
(n=29) (n=13) (n=17) (n=8) (n=34) (n=203)
Known recurrent 32 11 6 2 22 169
aberrations in total
del(11q) 9 (31%) 3 (23%) 0 1 (13%) 4 (12%) 27 (13%)
Average size of del(11q) 24.7 Mbp 26.1 Mbp - 29.9 Mbp 23.8 Mbp 29.5 Mbp
del(13q) 23 (79%) 4 (31%) 6 (35%) 0 15 (44%) 110 (54%)
Homozygous del(13q) 6 0 1 0 1
Average size del(13q) * 5.4 Mbp 13.6 Mbp 1.35 Mbp - 7.8 Mbp 4.6 Mbp
Combination of del(11q) 6 (21%) 3 (23%) 0 0 1 (3%) 10 (5%)
and del(13q)
Trisomy 12 0 3 (23%) 0 1 (13%) 2 (6%) 23 (11%)
del(17p) 0 1 (8%) 0 0 1 (3%) 9 (4%)
Samples from this study that overlapped with our array-based Swedish CLL study23 were not excluded from the large cohort, since this would have affected the comparison to
general CLL material’ in which IGHV3-21 and IGHV4-34 samples are represented (6.4% and 8.9% of samples, respectively). *Homozygous and heterozygous deletions of 13q
were combined to calculate average size (the average size was similar if they were divided into heterozygous/homozygous losses separately).
ed in the aforementioned study showed a low percentage
of CLL cells (7-15%) carrying del(13q) by applying FISH
(K. Stamatopoulos, unpublished data), which would have
remained undetected by SNP-array. 
What could be the reasons why subset #4 cases acquire
fewer genomic aberrations than subset #2 cases? We spec-
ulate that one important aspect could be the type of anti-
gen stimulation that subset #4 CLL cells experience.
Interestingly, IGHV4-34 antibodies are inherently autore-
active due to their recognition of the carbohydrate epi-
topes on the surface of red blood cells.33-35 Sequence alter-
ations by somatic hypermutation may be a means to elim-
inate or abrogate this autoreactivity, and thus, render
IGHV4-34-expressing cells sufficiently safe to enter the
peripheral repertoire.33,36 In analogy to this observation, it
is perhaps relevant to note that (i) IGHV4-34-expressing
CLL is most often mutated,10 and (ii) IGHV-mutated CLL
cells have been shown to be less responsive than their
unmutated counterparts upon IgM-crosslinking.37 Hence,
subset #4 CLL cells may represent a population of cells
which are relatively anergic upon BCR crosslinking.13
Additionally, we have recently demonstrated that subset
#4 CLL cells show extensive intraclonal diversification,
possibly due to ongoing antigenic stimulation.14,38
Following these lines of evidence, it seems plausible that
continuous (super)antigenic interaction may be necessary
for IGHV4-34 CLL clones to be maintained, yet the low-
proliferative “anergic” state cannot be overcome, thereby
preventing the accumulation of additional genomic alter-
ations. This is supported by our findings that subset #4
cases in general showed few copy-number aberrations,
carried only the good prognostic marker del(13q), and fol-
lowed a very indolent disease course.
Although our high density SNP-arrays could detect
some novel aberrations, few of these were overlapping in
subset and non-subset groups. For example, a concurrent
gain on chromosome 2q and a loss at 3p were identified in
two subset #2 cases. In IGHV4-34 CLL, three recurrent
aberrations were observed on chromosomes 2q, 7q and
14q but not in any particular subset. Furthermore, evalua-
tion of CNN-LOH events showed that small non-recur-
ring regions were frequent in all subset and non-subset
groups. When focusing on larger regions (>3 Mbp), over-
lapping CNN-LOH events were detected on chromosome
6 in two non-subset #4/16 patients and on chromosome
20 in one subset #2 and non-subset #2 case. As described
in previous CLL studies, we identified five cases with
CNN-LOH on chromosome 13q.23,39,40 This recurrent event
was detected in both IGHV3-21 and IGHV4-34 CLL with
no bias towards any subset/non-subset group. Since
CNN-LOH on 13q always harbored a homozygous
del(13q), this LOH might be of specific importance in CLL
biology although not specifically in relation to stereotypy.
In conclusion, high-density screening for genomic aber-
rations revealed differences in the genomic spectra
between subset #4 and subset #2/non-subset #2. As the
frequencies of del(13q) and del(11q) were particularly high
in subset #2, these deletions probably represent important
genetic events during the development of IGHV3-21 CLL.
In contrast, subset #4 patients exclusively showed del(13q)
and had a lower overall incidence of genomic aberrations.
These features suggest that genomic aberrations may not
play such a significant role in the pathogenesis of subset
#4 CLL cases, which is reflected by their indolent disease
course. 
Authorship and Disclosures
MiM, NC and RG performed research, analyzed data
and wrote the paper. AI, HG and MR performed bioinfor-
matic analyses. MJ and MaM performed laboratory work
and analyzed data. FR supervised the research. KK, HOA,
JJ, and FD provided samples and associated data. GJ, KS
and RR supervised the research and wrote the paper. 
The information provided by the authors about contributions
from persons listed as authors and in acknowledgments is avail-
able with the full text of this paper at www.haematologica.org.
Financial and other disclosures provided by the authors using the
ICMJE (www.icmje.org) Uniform Format for Disclosure of
Competing Interests are also available at www.haematologica.org.
M. Marincevic et al.
1524 haematologica | 2010; 95(9)
Figure 3. A high frequency of patients with IGHV3-21 with del(11q)
have a concomitant  del(13q). All 12 IGHV3-21 patients who carried
del(11q) are displayed. The upper three are non-subset #2 patients
and the remaining belong to subset #2.
References
1. Damle RN, Wasil T, Fais F, Ghiotto F,
Valetto A, Allen SL, et al. Ig V gene muta-
tion status and CD38 expression as novel
prognostic indicators in chronic lympho-
cytic leukemia. Blood. 1999;94(6):1840-7.
2. Hamblin TJ, Davis Z, Gardiner A, Oscier
DG, Stevenson FK. Unmutated Ig V(H)
genes are associated with a more aggres-
sive form of chronic lymphocytic
leukemia. Blood. 1999;94(6):1848-54.
3. Fais F, Ghiotto F, Hashimoto S, Sellars B,
Valetto A, Allen SL, et al. Chronic lympho-
cytic leukemia B cells express restricted sets
of mutated and unmutated antigen recep-
tors. J Clin Invest. 1998;102(8):1515-25.
4. Tobin G, Thunberg U, Johnson A, Thorn I,
Soderberg O, Hultdin M, et al. Somatically
mutated Ig V(H)3-21 genes characterize a
new subset of chronic lymphocytic
leukemia. Blood. 2002;99(6):2262-4.
5. Tobin G, Thunberg U, Johnson A, Eriksson
chromosome 11 chromosome 13
I, Soderberg O, Karlsson K, et al. Chronic
lymphocytic leukemias utilizing the VH3-
21 gene display highly restricted
Vlambda2-14 gene use and homologous
CDR3s: implicating recognition of a com-
mon antigen epitope. Blood. 2003;101(12):
4952-7.
6. Messmer BT, Albesiano E, Efremov DG,
Ghiotto F, Allen SL, Kolitz J, et al. Multiple
distinct sets of stereotyped antigen recep-
tors indicate a role for antigen in promoting
chronic lymphocytic leukemia. J Exp Med.
2004;200(4):519-25.
7. Widhopf GF 2nd, Rassenti LZ, Toy TL,
Gribben JG, Wierda WG, Kipps TJ. Chronic
lymphocytic leukemia B cells of more than
1% of patients express virtually identical
immunoglobulins. Blood. 2004;104(8):
2499-504.
8. Tobin G, Thunberg U, Karlsson K, Murray
F, Laurell A, Willander K, et al. Subsets with
restricted immunoglobulin gene rearrange-
ment features indicate a role for antigen
selection in the development of chronic
lymphocytic leukemia. Blood. 2004;104(9):
2879-85.
9. Stamatopoulos K, Belessi C, Moreno C,
Boudjograh M, Guida G, Smilevska T, et al.
Over 20% of patients with chronic lym-
phocytic leukemia carry stereotyped recep-
tors: Pathogenetic implications and clinical
correlations. Blood. 2007;109(1):259-70.
10. Murray F, Darzentas N, Hadzidimitriou A,
Tobin G, Boudjogra M, Scielzo C, et al.
Stereotyped patterns of somatic hypermu-
tation in subsets of patients with chronic
lymphocytic leukemia: implications for the
role of antigen selection in leukemogenesis.
Blood. 2008;111(3):1524-33.
11. Darzentas N, Hadzidimitriou A, Murray F,
Hatzi K, Josefsson P, Laoutaris N, et al. A
different ontogenesis for chronic lympho-
cytic leukemia cases carrying stereotyped
antigen receptors: molecular and computa-
tional evidence. Leukemia. 2010;24(1):125-
32.
12. Ghia P, Stamatopoulos K, Belessi C,
Moreno C, Stella S, Guida G, et al.
Geographic patterns and pathogenetic
implications of IGHV gene usage in chron-
ic lymphocytic leukemia: the lesson of the
IGHV3-21 gene. Blood. 2005;105(4):1678-
85.
13. Potter KN, Mockridge CI, Neville L,
Wheatley I, Schenk M, Orchard J, et al.
Structural and functional features of the B-
cell receptor in IgG-positive chronic lym-
phocytic leukemia. Clin Cancer Res.
2006;12(6):1672-9.
14. Kostareli E, Hadzidimitriou A, Stavroyianni
N, Darzentas N, Athanasiadou A, Gounari
M, et al. Molecular evidence for EBV and
CMV persistence in a subset of patients
with chronic lymphocytic leukemia
expressing stereotyped IGHV4-34 B-cell
receptors. Leukemia. 2009;23(5):919-24.
15. Thorselius M, Krober A, Murray F,
Thunberg U, Tobin G, Buhler A, et al.
Strikingly homologous immunoglobulin
gene rearrangements and poor outcome in
VH3-21-using chronic lymphocytic
leukemia patients independent of geo-
graphic origin and mutational status. Blood.
2006;107(7):2889-94.
16. Ghia EM, Jain S, Widhopf GF 2nd, Rassenti
LZ, Keating MJ, Wierda WG, et al. Use of
IGHV3-21 in chronic lymphocytic
leukemia is associated with high-risk dis-
ease and reflects antigen-driven, post-ger-
minal center leukemogenic selection.
Blood. 2008;111(10):5101-8.
17. Bomben R, Dal Bo M, Capello D, Forconi F,
Maffei R, Laurenti L, et al. Molecular and
clinical features of chronic lymphocytic
leukaemia with stereotyped B cell recep-
tors: results from an Italian multicentre
study. Br J Haematol. 2009;144(4):492-506.
18. Dohner H, Stilgenbauer S, Benner A,
Leupolt E, Krober A, Bullinger L, et al.
Genomic aberrations and survival in chron-
ic lymphocytic leukemia. N Engl J Med.
2000;343(26):1910-6.
19. Juliusson G, Oscier DG, Fitchett M, Ross
FM, Stockdill G, Mackie MJ, et al.
Prognostic subgroups in B-cell chronic lym-
phocytic leukemia defined by specific chro-
mosomal abnormalities. N Engl J Med.
1990;323(11):720-4.
20. Athanasiadou A, Stamatopoulos K,
Gaitatzi M, Stavroyianni N, Fassas A,
Anagnostopoulos A. Recurrent cytogenetic
findings in subsets of patients with chronic
lymphocytic leukemia expressing IgG-
switched stereotyped immunoglobulins.
Haematologica. 2008;93(3):473-4.
21. Hallek M, Cheson BD, Catovsky D,
Caligaris-Cappio F, Dighiero G, Dohner H,
et al. Guidelines for the diagnosis and treat-
ment of chronic lymphocytic leukemia: a
report from the International Workshop on
Chronic Lymphocytic Leukemia updating
the National Cancer Institute-Working
Group 1996 guidelines. Blood. 2008;
111(12):5446-56.
22. Rabbee N, Speed TP. A genotype calling
algorithm for affymetrix SNP arrays.
Bioinformatics. 2006;22(1):7-12.
23. Gunnarsson R, Isaksson A, Mansouri M,
Goransson H, Jansson M, Cahill N, et al.
Large but not small copy-number alter-
ations correlate to high-risk genomic aber-
rations and survival in chronic lymphocytic
leukemia: a high-resolution genomic
screening of newly diagnosed patients.
Leukemia. 2010;24(1):211-5.
24. Sebat J, Lakshmi B, Troge J, Alexander J,
Young J, Lundin P, et al. Large-scale copy
number polymorphism in the human
genome. Science. 2004;305(5683):525-8.
25. Redon R, Ishikawa S, Fitch KR, Feuk L,
Perry GH, Andrews TD, et al. Global varia-
tion in copy number in the human genome.
Nature. 2006;444(7118):444-54.
26. McCarroll SA, Kuruvilla FG, Korn JM,
Cawley S, Nemesh J, Wysoker A, et al.
Integrated detection and population-genet-
ic analysis of SNPs and copy number varia-
tion. Nat Genet. 2008;40(10):1166-74.
27. Goransson H, Edlund K, Rydaker M,
Rasmussen M, Winquist J, Ekman S, et al.
Quantification of normal cell fraction and
copy number neutral LOH in clinical lung
cancer samples using SNP array data. PLoS
One. 2009;4(6):e6057.
28. Herve M, Xu K, Ng YS, Wardemann H,
Albesiano E, Messmer BT, et al. Unmutated
and mutated chronic lymphocytic
leukemias derive from self-reactive B cell
precursors despite expressing different anti-
body reactivity. J Clin Invest. 2005;115(6):
1636-43.
29. Chiorazzi N, Hatzi K, Albesiano E. B-cell
chronic lymphocytic leukemia, a clonal dis-
ease of B lymphocytes with receptors that
vary in specificity for (auto)antigens. Ann N
Y Acad Sci. 2005;1062:1-12.
30. Lanemo Myhrinder A, Hellqvist E,
Sidorova E, Soderberg A, Baxendale H,
Dahle C, et al. A new perspective: molecu-
lar motifs on oxidized LDL, apoptotic cells,
and bacteria are targets for chronic lympho-
cytic leukemia antibodies. Blood.
2008;111(7):3838-48.
31. Catera R, Silverman GJ, Hatzi K, Seiler T,
Didier S, Zhang L, et al. Chronic lympho-
cytic leukemia cells recognize conserved
epitopes associated with apoptosis and oxi-
dation. Mol Med. 2008;14(11-12):665-74.
32. Chu CC, Catera R, Hatzi K, Yan XJ, Zhang
L, Wang XB, et al. Chronic lymphocytic
leukemia antibodies with a common
stereotypic rearrangement recognize non-
muscle myosin heavy chain IIA. Blood.
2008;112(13):5122-9.
33. Bhat NM, Bieber MM, Chapman CJ,
Stevenson FK, Teng NN. Human antilipid A
monoclonal antibodies bind to human B
cells and the i antigen on cord red blood
cells. J Immunol. 1993;151(9):5011-21.
34. Spellerberg M, Chapman C, Hamblin T,
Stevenson F. Dual recognition of lipid A and
DNA by human antibodies encoded by the
VH4-21 gene. A possible link between
infection and lupus. Ann NY Acad Sci.
1995;764:427-32.
35. Li Y, Spellerberg MB, Stevenson FK, Capra
JD, Potter KN. The I binding specificity of
human VH 4-34 (VH 4-21) encoded anti-
bodies is determined by both VH frame-
work region 1 and complementarity deter-
mining region 3. J Mol Biol. 1996;256(3):
577-89.
36. Pugh-Bernard AE, Silverman GJ, Cappione
AJ, Villano ME, Ryan DH, Insel RA, et al.
Regulation of inherently autoreactive VH4-
34 B cells in the maintenance of human B
cell tolerance. J Clin Invest. 2001;108(7):
1061-70.
37. Mockridge CI, Potter KN, Wheatley I,
Neville LA, Packham G, Stevenson FK.
Reversible anergy of sIgM-mediated signal-
ing in the two subsets of CLL defined by
VH-gene mutational status. Blood.
2007;109(10):4424-31.
38. Sutton LA, Kostareli E, Hadzidimitriou A,
Darzentas N, Tsaftaris A, Anagnostopoulos
A, et al. Extensive intraclonal diversifica-
tion in a subgroup of chronic lymphocytic
leukemia patients with stereotyped
IGHV4-34 receptors: implications for ongo-
ing interactions with antigen. Blood.
2009;114(20):4460-8.
39. Pfeifer D, Pantic M, Skatulla I, Rawluk J,
Kreutz C, Martens UM, et al. Genome-
wide analysis of DNA copy number
changes and LOH in CLL using high-densi-
ty SNP arrays. Blood. 2007;109(3):1202-10.
40. Lehmann S, Ogawa S, Raynaud SD, Sanada
M, Nannya Y, Ticchioni M, et al. Molecular
allelokaryotyping of early-stage, untreated
chronic lymphocytic leukemia. Cancer.
2008;112(6):1296-305.
High-density genomic arrays in CLL subsets
haematologica | 2010; 95(9) 1525
